Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Valley Brook Capital Group Inc.

Valley Brook Capital Group Inc. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,885 shares of the medical research company’s stock after purchasing an additional 25 shares during the quarter. Thermo Fisher Scientific comprises about 2.2% of Valley Brook Capital Group Inc.’s investment portfolio, making the stock its 11th largest holding. Valley Brook Capital Group Inc.’s holdings in Thermo Fisher Scientific were worth $3,022,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Advisory Alpha LLC lifted its holdings in shares of Thermo Fisher Scientific by 77.4% in the first quarter. Advisory Alpha LLC now owns 779 shares of the medical research company’s stock valued at $453,000 after buying an additional 340 shares during the period. Advisory Services Network LLC boosted its position in shares of Thermo Fisher Scientific by 2.7% during the 1st quarter. Advisory Services Network LLC now owns 8,869 shares of the medical research company’s stock valued at $5,155,000 after purchasing an additional 231 shares in the last quarter. CFO4Life Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $234,000. Empirical Finance LLC lifted its stake in Thermo Fisher Scientific by 3.4% during the first quarter. Empirical Finance LLC now owns 14,143 shares of the medical research company’s stock valued at $8,220,000 after purchasing an additional 467 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in Thermo Fisher Scientific by 30.2% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 45,451 shares of the medical research company’s stock worth $26,417,000 after buying an additional 10,547 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $557.89, for a total value of $3,263,656.50. Following the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,150 shares of company stock worth $10,094,925 in the last quarter. 0.34% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TMO shares. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price objective for the company. Bernstein Bank lifted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Stephens started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target on the stock. Finally, Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Stock Up 0.1 %

NYSE:TMO traded up $0.30 during trading hours on Thursday, reaching $559.98. The company’s stock had a trading volume of 102,639 shares, compared to its average volume of 1,454,589. Thermo Fisher Scientific Inc. has a one year low of $437.26 and a one year high of $627.88. The business’s 50-day moving average is $596.33 and its 200-day moving average is $583.80. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market cap of $214.19 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 3.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period in the previous year, the company earned $5.69 EPS. The company’s revenue for the quarter was up .2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.